@Article{,
AUTHOR = {Ulf W. Tunn, Amulf Stenzl, Wolfgang Schultze-Seemann, Arne Strauss, Manfred Kindler, Kurt Miller, Manfred P. Wirth, Niko Zantl, Matthias Schulze, Christoph May, Amelie Ruebel, Katrin Birkholz, Viktor Gruenwald},
TITLE = {Positive effects of zoledronate on skeletal-related events in patients with renal cell  cancer and bone metastases},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {19},
YEAR = {2012},
NUMBER = {3},
PAGES = {6261--6267},
URL = {http://www.techscience.com/CJU/v19n3/61800},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Approximately 30% of patients with renal cell cancer (RCC) develop bone metastasis, causing skeletal-related events (SREs): pathologic fracture, spinal cord compression, surgery to bone, and radiotherapy. Zoledronic acid demonstrated significant clinical benefit in RCC patients in a retrospective analysis. The primary objective of this prospective study was to evaluate the proportion of patients experiencing ≥ 1 SRE during 12 months of zoledronic acid treatment and to verify the retrospective data.<br/>
<b>Materials and methods:</b> Fifty patients with histologically confirmed RCC and evidence of ≥ 1 cancer-related bone lesion, and ≤ 3 prior bisphosphonate applications were enrolled across 19 German centers between 2004 and 2007. Patients received 4 mg zoledronic acid every 3 weeks for 12 months, followed by a follow-up period assessing overall survival for an additional 12 months. Bone lesions were diagnosed using bone scan or MRI-quickscan. At least one lesion had to be confirmed by x-ray, CT, or MRI scan. Additional bone scans were performed after completion of study treatment and when clinically indicated. In cases of suspected or evident SRE, radiological confirmation was required.<br/>
<b>Results:</b> A total of 49 out of 50 enrolled patients were treated. Only 11 patients (22.4%) experienced any SRE by month 12. Patients with > 6 lesions and higher baseline MSKCC (Memorial Sloan-Kettering Cancer Center) scores had a higher risk for SREs. Zoledronic acid was generally well tolerated, affirming its known safety profile.<br/>
<b>Conclusions:</b> This prospective study confirms prior findings regarding the efficacy of zoledronic acid in patients with metastatic (m)RCC, supporting its beneficial use in this patient population.},
DOI = {}
}